JAGUAR HEALTH, INC. Stock Split Ratio
JAGUAR HEALTH, INC. (JAGX) reported Stock Split Ratio of 2.85% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2026-08-19
- JAGUAR HEALTH, INC. stockholders' equity note, stock split, conversion ratio for fiscal 2019 was 100.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio as first filed | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 6 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 2.85% 10-Q · filed 2026-08-19 | ||||
| 2026-04-20 | 4.00% 10-Q · filed 2026-08-19 | ||||
| 2025-06-30 | 2.80% 10-Q · filed 2026-08-19 | ||||
| 2025-03-18 | 4.00% 10-Q · filed 2026-08-19 | ||||
| 2024-05-23 | 1.67% 10-K · filed 2026-04-07 | ||||
| 2023-01-23 | 1.33% 10-Q · filed 2024-08-13 | ||||
| 2021-09-08 | 33.00% 10-Q · filed 2024-08-13 | ||||
| 2021-09-03 | 33.00% 10-Q · filed 2024-05-14 | 3333.00% 10-Q · filed 2021-11-17 | |||
| 2019-12-31 | 100.00% 10-K · filed 2021-03-31 | ||||
| 2019-06-30 | 1.50% 10-K · filed 2020-04-03 | ||||
| 2019-06-03 | 1.43% 10-K · filed 2021-03-31 | 1.50% 10-Q · filed 2019-08-14 | |||
| 2019-05-29 | 6.67% 10-Q · filed 2019-11-14 | ||||
| 2018-06-30 | 6.67% 10-K · filed 2020-04-03 | ||||
| 2018-05-29 | 6.67% 10-K · filed 2020-04-03 | ||||
| 2018-05-18 | 6.67% 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |